Diagnostic performance of the assays at manufacturers’ decision levels considering different non-RA control subgroups for receiver-operator characteristic (ROC) analysis.
| Subgroups for ROC Analysis | AxSYM | Anti-CCP, U/ml | Anti-CCP3, U | Anti-CCP2, U | Anti-MCV, U/ml | RF, IU/ml | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AUC, % (95% CI) | Sn, % | Sp, % | AUC, % (95% CI) | Sn, % | Sp, % | AUC, % (95% CI) | Sn, % | Sp, % | AUC, % (95% CI) | Sn, % | Sp, % | AUC, % (95% CI) | Sn, % | Sp, % | |
| Non-RA Inflammatory Disease | |||||||||||||||
| RA/SLE | 89.3 (83.7–94.8) | 80.6 | 84.2 | 87.5 (81.6–93.4) | 61.9 | 97.4 | 83.2 (76.4–89.9) | 60.2 | 97.4 | 70.2 (61.3–79.1) | 49.8 | 86.8 | 82.7 (76–89.5) | 67.8 | 97.4 |
| RA/pSS | 83 (74.6–91.5) | 80.6 | 70.6 | 83.4 (75.4–91.4) | 61.3 | 97.1 | 82.4 (74.6–90.2) | 59.7 | 100 | 70.3 (59.7–80.9) | 49.8 | 88.2 | 73.6 (63.2–83.9) | 67.8 | 76.5 |
| RA/SLE+pSS | 87.3 (81.8–92.9) | 80.6 | 80 | 86.2 (80.6–91.9) | 61.3 | 97.3 | 82.9 (76.5–89.3) | 59.7 | 98.2 | 70.2 (62–78.4) | 49.8 | 87.3 | 79.9 (72.9–86.9) | 67.8 | 90.9 |
| Non-RA Non-Inflammatory Disease | |||||||||||||||
| RA/OA | 96.7 (93.4–100) | 80.6 | 100 | 90.2 (82.3–98.1) | 61.9 | 100 | 81 (71.5–90.6) | 59.7 | 100 | 75.3 (64.5–86.1) | 49.8 | 100 | 82.1 (73.4–90.8) | 67.8 | 93.9 |
| RA/HC | 89.6 (83.8–95.5) | 80.6 | 88.2 | 86.2 (78.6–93.8) | 61.9 | 94.1 | 79.8 (71–88.5) | 59.7 | 100 | 75.3 (65.8–84.8) | 49.8 | 100 | 82.8 (75.1–90.5) | 67.8 | 94.1 |
| RA/OA+HC | 92.4 (87.8–97) | 80.6 | 92.9 | 87.7 (81.5–94) | 61.9 | 96.4 | 80.3 (72.6–87.9) | 59.7 | 100 | 75.3 (66.8–83.7) | 49.8 | 100 | 82.5 (75.4–89.6) | 67.8 | 92.9 |
AUC: area under the curve; Sn: sensitivity; Sp: specificity; pSS: primary Sjögren’s syndrome; HC: healthy controls.